Bone disease induced by phenytoin therapy: Clinical and experimental study

European Neurology

Volumn 62, Issue 4, 2009, Pages 219-230

  Moro Alvarez, M J ^a,e   Diaz Curiel M ^b   De La Piedra, C ^b   Marinoso M L ^c   Carrascal, M T ^d  

^a Metabolic Bone Disease Unit H   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

^e HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

Author keywords

Anticonvulsants; Biological markers; Bone mineral density; Histomorphometry; Phenytoin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALBUMIN; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIFEDIOL; CALCITRIOL; CALCIUM; CARBAMAZEPINE; CREATININE; GABAPENTIN; GAMMA GLUTAMYLTRANSFERASE; HYDROXYPROLINE; OSTEOCALCIN; PARATHYROID HORMONE; PHENOBARBITAL; PHENYTOIN; PHOSPHORUS; PRIMIDONE; VALPROIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE FRAGILITY; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; EPILEPSY; EXPERIMENTAL STUDY; FEMALE; FEMUR; FRACTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; KIDNEY TUBULE ABSORPTION; LUMBAR SPINE; MALE; NONHUMAN; OSSIFICATION; OSTEOID; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RAT; TRABECULAR BONE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADULT; AGED; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; EPILEPSY; FEMALE; FEMUR; HUMANS; MALE; MIDDLE AGED; MINERALS; PATIENT SELECTION; PHENYTOIN; RATS; RATS, WISTAR; SPINE; TORSION, MECHANICAL;

EID: 67651006539     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229309     Document Type: Article

References (73)

1. Merrit HH, Putnam TJ: Sodium diphenyl hydantoinate in treatment of convulsive disorders. JAMA 1938; 111: 1068-1073.
2. Livingston S, Berman W, Pauli LL: Anticon-vulsant drugs and vitamin D metabolism. JAMA 1973; 224: 1634-1635.
3. Hahn TJ, Hendin BA, Scharp CR, Haddad JG: Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972; 287: 900-904.
4. Matheson RT, Herbst JJ, Jubiz W, Freston JW, Tolman KG: Absorption and biotransformation of cholecalciferol in drug-induced os-teomalacia. J Clin Pharmacol 1976; 16: 426-432.
5. Fitzpatrick LA: Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004; 5(suppl 2):S3-S15.
6. Petty SJ, medication and bone health. Osteoporos Int 2007; 18: 129-142.
7. Hahn TJ, Avioli LU: Anticonvulsant osteo-malacia. Arch Intern Med 1975; 135: 997-1000.
8. Hahn TJ, Scharp CR, Richardson CA, Hal-stead LR, Kahn AJ, Teielbaum SL: Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978; 62: 406-414.
9. Dietrich OW, Duffield R: Effects of diphe-nylhydantoin on synthesis of collagen and noncollagen protein in tissue culture. Endocrinology 1980; 106: 606-610.
10. Dai I, Ohishi K, Kataoka M, Kido J, Nagata T: Effect of phenytoin on osteoblast differentiation in rat calvaria cell culture. Bone 1998; 23:S-419.
11. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA: Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000; 108: 37-43.
12. Nakade O, Baylink DJ, Lau KH: Osteogenic actions of phenytoin human bone cells are mediated in part by TGF-. J Bone Miner Res 1996; 11: 1880-1888.
13. Ohta T, Schiltz P, Matsuyama T, Wergedal JE, Baylink DJ, Lau KHW: Phenytoin is an osteogenic agent in vitro and in vivo. J Bone Miner Res 1991;S125, abstract 170.
14. Ohta T, Wergedal JE, Gruber HE, Baylink DJ, William Lau KH: Low dose phenytoin is an osteogenic agent in the rat. Calcif Tissue Int 1995; 56: 42-48.
15. Vernillo AT, Rifkin BR, Hauschka PV: Phe-nytoin affects osteocalcin secretion from os-teoblastic rat osteosarcoma 17/2.8 cells in cultures. Bone 1990; 11: 309-312.
16. Dent CE, Richens A, Rowe DJF, Stamps TCB: Osteomalacia with lon-term anticonvulsant therapy in epilepsy. Br Med J 1970;iv:69-72.
17. Hunter J, Maxwell JD, Stewart DA, Parsons V, Williams R: Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J 1971;iv:202-204.
18. Johnell O, Nilsson, Anders W, Wiklund PE: Bone morphology in epileptics. Calcif Tissue Int 1979; 28: 93-97.
19. Richens A, Rowe DJF: Disturbance of calcium metabolism by convulsant drugs. Br Med J 1970;iv:73-76.
20. Tolman KG, Jubbiz W, Sannella JJ, Madsen JA, Belsey RE, Goldsmith RS, Freston JW: Osteomalacia associated with anticonvul-sant drug therapy in mentally retarded children. Pediatrics 1975; 56: 45-50.
21. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL: Antiepileptic drug use increases rates of bone loss in older women: a prospective study.TJ, Wark NeurologyJD: 2004; 62:2051-2057.
22. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA: Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000; 108: 37-43.
23. Lau KHW, Nakade O, Barr B, Taylor AK, Houchin K, Baylink DJ: Phenytoin increases markers of osteogenesis for the human species in vitro and in vivo. J Clin Endocrinol Metab 1995; 80: 2347-2353.
24. Ohta T, Wergedal JE, Gruber HE, Baylink DJ, William Lau KH: Phenytoin and fluoride act in concert to stimulate bone formation and to increase bone volume in adult male rats. Calcif Tissue Int 1995; 56: 390-397.
25. Parfitt AM: Osteomalacia and phenytoin therapy. Ann Intern Med 1995; 122: 632.
26. Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BG: Decreases serum ionized and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endo-crinol Metab 1984; 58: 1003-1009.
27. Amman P, Rizzoli R, Bonjour JP: Preclinical evaluation of new therapeutic agents for osteoporosis; in Meurnier JP (ed): Osteoporosis: Diagnosis and Management. London, Martin Duwitz, 1988, pp 257-273.
28. Eddy DM, Conrad CJ, Cummings SR, et al: Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 1998; (suppl 4):S21-S24.
29. Garnero P, Delmas PD: New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996; 59:S2-S9.
30. Delmas PD: Biochemical markers of bone remodeling in osteoporosis; in Papoulus SE, Lips P, Pols HAP, Johnston CC, Delmas PD (eds): Osteoporosis 1996 International Congress Series 1118. Elsevier, Amsterdam, 1996, pp 191-204.
31. Aersen J, Audekercke RV, Talalaj M, Geusens P, Bramm E, Dequeker J: Effect of 1 alfa-vitamin D3 and estrogen therapy on cortical bone mechanical properties in the ovariec-tomized rat model. Endocrinology 1996; 137: 1358-1364.
32. Hodgskinson R, Njeh CF, Currey JD, Lang-ton CM: The ability of ultrasound velocity to predict the stifness of cancellous bone in vitro. Bone 1997; 21: 183-190.
33. Järvinen TLN, Sievänen H, Kannus P, Järvi-nen M: Dual-energy X-ray absorptiometry in predicting mechanical characteristics of rat femur. Bone 1998; 22: 551-558.
34. Liang Y, Zhao J, Audekercke RV, Dequeker J, Geusens P: Effect of low-dose long-term sodium fluoride preventive treatment on rat bone mass and biomechanical properties. Calcif Tissue Int 1996; 58: 30-39.
35. Díaz Curiel M, Carrasco de la norato Perez I, et al: Study of bone mineral density in lumbar spine and femoral neck -epilepticin a Spanish population. Osteoporosis Int 1997; 7: 59-64.
36. Díaz Curiel M, Turbí Disla C, Rapado A, García JJ: Prevalencia de osteopenia y osteoporosis densitométrica en la culina 1997; 6: 13-16.
37. Díaz Curiel M: Prevalencia de osteoporosis densitométrica en la Díaz Curiel M, Díez Perez A, Gomez Alonso C (eds): Nuevas fronteras en el estudio de la densidad mineral Poulenc Rorer, 1996, pp 95-117.
38. Kanis JA, Melton LJ III, Christiansen C, Johnston C, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141.
39. Gala JL, Díaz Curiel M, De la Piedra C, Cas-tilla C, Torralbo M: Bone mass assessment in rats by dual energy X-ray absorptiometry. Br J Radiol 1998; 71: 754-758.
40. Li CY, Chuda RA, Lam WKW: Acid phos-phatases in human plasma. J Lab Clin Med 1973; 82: 446-460.
41. Diaz Martin MA, De la Piedra C, Porres A, Gomez Gerique JA: Interferencia de la de la fosfafatasa suero y Enf Metab Oseas 1992; 1: 347-365.
42. Calero JA, De la Piedra C, Díaz Curiel M: Usefulness of serum pyridinoline cross-linked carboxy-terminal telopeptides of type I collagen and osteocalcin in the study of the bone resorption rate in oophorectomized rats. Miner Electrolyte Metab 1998; 24: 303-306.
43. Parfitt AM, Drezner MK, Glorieux FH, et al: Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res 1987; 2: 595-610.
44. Larsen K: Creatinine by a reaction-kinetic principle. Clin Chim Acta 1972; 41: 209-217.
45. Hasen JL, Freier EF: The measurement of serum magnesium by atomic absorption spec-trophotometry (AAS). Am J Med Technol 1967; 33: 158-166.
46. Trudeau DL, Freier EF: Determination of calcium in urine and serum by atomic absorption spectrophotometry (AAS) Clin Chem 1967; 13: 101-114.
47. Fiske CH, Subbarow Y: The colorimetric determination of phosphorus. J Biol Chem 1925; 66: 375-400.
48. Szasz G: Reaction rate method for-gluta-myl tranferase activity in serum. Clin Chem 22: 1976; 2051-2055.
49. Colton T (ed): Statistics in Medicine. Boston, Little, Brown, 1974, p 164.
50. Fuleihan GE, Dib L, Yamout B, Sawaya R , Mikati MA: Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 2008; 43: 149-155.
51. Stephen LJ, McLellan AR, Harrison JH, Shapiro D, Dominiczak MH, Sills GJ, Brodie MJ: Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999; 8: 339-342.
52. Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W: Anti-epileptic drug-induced bone loss in young male patients who have seizures. Arch Neu-rol 2002; 59: 781-786.
53. Stephen LJ, McLellan AR, Harrison JH, et al: Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999; 8: 339-342.
54. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G: Effect of an-tiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58: 1348-1353.
55. Pack AM, Olarte LS, Morrell MJ, Flaster E, Resor SR, Shane E: Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003; 4: 169-174.
56. Akin R, Okutan V, Sarici U, Altunbas A, Gokcay E: Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998; 19: 129-131.
57. Välimäki MJ, Tiihonen M, Laitinen K, et al: Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on epileptic drugs. J Bone Miner Res 1994; 9: 631-637.
58. Souverein P, Webb DJ, Petri H, Weil J, Van Staa TP, Egberts T: Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005; 46: 304-310.
59. Vestergaard P: Epilepsy, osteoporosis and fracture risk a meta-analysis. Acta Neurol Scand 2005; 112: 277-286.
60. Ensrud KE, Blackwell T, Mangione CM, et al: Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163: 949-957.
61. Takeshita N, Seino Y, Ishida H, et al: Increased circulating levels of-carboxyglu-tamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif Tissue Int 1989; 44: 80-85.
62. Traverso A, Boccignone E, Tanganelli P, Re-gesta G, Ottonello GA, Giordano G: Bone resorption in epileptic patients on chronic treatment assessed by the measurement of urinary pyridinium crosslinks and urinary crosslinked N-telopeptides of bone type I collagen. Bone 1995; 16(108):92.
63. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57: 445-449.
64. Genuth SM, Klein L, Rabinovich S, King KC: Osteomalacia accompanying chronic anti-convulsant therapy. J Clin Endocrinol Metab 1972; 35: 378-386.
65. Ashworth B, Horn DB: Evidence of osteoma-lacia in an outpatient group of adult epileptics. Epilepsia 1977; 18: 37-43.
66. Bogliun G, Beghi E, Crespi V, Delodovici L, metabolism. Acta Neurol Scand 1986; 74: 284-288.
67. Fogelman I, Gray JM, Gardner MD, et al: Do anticonvulsant drugs commonly induce os-teomalacia. Scott Med J 1982; 27: 136-142.
68. Hoikka V, Savolainen K, Alhava EM, et al: Anticonvulsant osteomalacia in epileptic outpatient. Ann Clin Res 1982; 14: 129-132.
69. Mosekilde L, Melsen F: Dynamic differences in trabecular bone remodeling between patients after jejuno-ileal bypass for obesity and epileptic patients receiving anticonvul-sant therapy. Metab Bone Dis Relat Res 1980; 2: 77-82.
70. Herrath DV, Kraft D, Schaefer K, Koeppe P: Influence of phenobarbital and diphenylhy-dantoin on vitamin D metabolism and calcium retention in rats. Res Exp Med 1972; 158: 194-204.
71. Frame B: Hypocalcemia and osteomalacia associated with anticonvulsant therapy. Ann Intern Med 1971; 74: 294-295.
72. Pylypchuck G, Oreopoulos DG, Wilson DR, et al: Calcium metabolism in adult outpatients with epilepsy receiving long-term an-ticonvulsant therapy. Can Med Assoc J 1978; 118: 635-638.
73. De la Piedra C, Rios I, Ramos de Bello J, Pe-ramo B, Rapado A: El laboratorio en el diag-Rev Esp Enf Metab Oseas 1995; 4: 44-49.